Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2713637 | 0.87 | KDM4E (0.46) | TSHRF10L3MBTL1CA12CA1 | |
| SCHEMBL1312979 | 0.83 | POLB (0.57) | TSHRF10L3MBTL1CYP1A2GABRA5 | |
| SCHEMBL12113233 | 0.83 | MAPK8 (0.50) | TSHRL3MBTL1CA9CYP1A2ALDH1A1 | |
| SCHEMBL3802758 | 0.83 | ALDH1A1 (0.50) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL5820624 | 0.83 | ALDH1A1 (0.49) | TSHRL3MBTL1CA12CA1CA2 | |
| SCHEMBL424710 | 0.83 | L3MBTL1 (0.48) | TSHRL3MBTL1CA12CA1CA2 | |
| SCHEMBL6409775 | 0.81 | POLB (0.63) | TSHRF10CA12CA1CA2 | |
| SCHEMBL4251382 | 0.80 | HSP90AA1 (0.58) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL30828955 | 0.78 | L3MBTL1 (0.49) | TSHRL3MBTL1CA12CA1CA2 | |
| SCHEMBL3283452 | 0.75 | ALDH1A1 (0.50) | TSHRL3MBTL1CYP1A2MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809538-B2 | Piperidine-containing compounds and use thereof | ARRAY BIOPHARMA INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809538-B2 | Piperidine-containing compounds and use thereof | ARRAY BIOPHARMA INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20110275608-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275608-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2375899-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | Array Biopharma, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010080864-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080864-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275608-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | NOS1, NOS2, ASS1 | TSHR 3958/4885F10 4375/4885L3MBTL1 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.